KR20050085009A - Ｈｃｖ에 대한 백신 - Google Patents

Ｈｃｖ에 대한 백신 Download PDF

Info

Publication number
KR20050085009A
KR20050085009A KR1020057008793A KR20057008793A KR20050085009A KR 20050085009 A KR20050085009 A KR 20050085009A KR 1020057008793 A KR1020057008793 A KR 1020057008793A KR 20057008793 A KR20057008793 A KR 20057008793A KR 20050085009 A KR20050085009 A KR 20050085009A
Authority
KR
South Korea
Prior art keywords
hcv
core
protein
vaccine
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057008793A
Other languages
English (en)
Korean (ko)
Inventor
사라 브레트
폴 앤드류 햄블린
루이즈 오길비
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20050085009A publication Critical patent/KR20050085009A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020057008793A 2002-11-15 2003-11-13 Ｈｃｖ에 대한 백신 Ceased KR20050085009A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine
GB0226722.7 2002-11-15

Publications (1)

Publication Number Publication Date
KR20050085009A true KR20050085009A (ko) 2005-08-29

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020057008793A Ceased KR20050085009A (ko) 2002-11-15 2003-11-13 Ｈｃｖ에 대한 백신
KR1020057008794A Ceased KR20050085010A (ko) 2002-11-15 2003-11-13 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057008794A Ceased KR20050085010A (ko) 2002-11-15 2003-11-13 백신

Country Status (21)

Country Link
US (4) US20060135451A1 (https=)
EP (2) EP1560844A1 (https=)
JP (2) JP2006524181A (https=)
KR (2) KR20050085009A (https=)
CN (2) CN1738834A (https=)
AR (1) AR041964A1 (https=)
AU (2) AU2003288072A1 (https=)
BR (2) BR0316291A (https=)
CA (2) CA2504715A1 (https=)
CO (1) CO5700833A2 (https=)
GB (1) GB0226722D0 (https=)
IS (2) IS7830A (https=)
MA (2) MA27700A1 (https=)
MX (2) MXPA05005203A (https=)
NO (2) NO20052136L (https=)
NZ (2) NZ539998A (https=)
PL (2) PL376967A1 (https=)
RU (2) RU2323744C2 (https=)
TW (1) TW200502246A (https=)
WO (2) WO2004046175A1 (https=)
ZA (2) ZA200503802B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN102614510A (zh) 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
EP1981537B1 (en) * 2006-01-04 2015-08-26 GlaxoSmithKline Biologicals S.A. HCV E1E2 MF59-adjuvanted protein plus HCV E1E2 encoding alphavirus vector for eliciting HCV-specific T cells.
ATE556136T1 (de) * 2006-03-09 2012-05-15 Transgene Sa Nichtstrukturelles hcv-fusionsprotein
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
JP2011529077A (ja) * 2008-07-24 2011-12-01 アデュロ バイオテック Ｃ型肝炎の治療のための組成物および方法
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
DE69533167D1 (de) * 1994-10-05 2004-07-22 Apollon Inc Impfstoffe gegen den hepatitis b und c virus
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
AU717542B2 (en) * 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
WO2001004149A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
CA2389206C (en) * 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
CA2390082C (en) * 1999-11-24 2010-06-29 Chiron Corporation Novel hcv non-structural polypeptide
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2005113691A (ru) 2006-01-27
BR0316244A (pt) 2005-10-04
RU2363492C2 (ru) 2009-08-10
ZA200503802B (en) 2006-08-30
NO20052149D0 (no) 2005-05-02
MXPA05005202A (es) 2006-01-27
IS7831A (is) 2005-04-28
CO5700833A2 (es) 2006-11-30
US20060135451A1 (en) 2006-06-22
JP2006524181A (ja) 2006-10-26
BR0316291A (pt) 2005-10-11
JP2006518331A (ja) 2006-08-10
AU2003288072A1 (en) 2004-06-15
PL376967A1 (pl) 2006-01-23
NZ539999A (en) 2008-03-28
IS7830A (is) 2005-04-28
RU2005113692A (ru) 2006-01-27
CA2504715A1 (en) 2004-06-03
CN1738834A (zh) 2006-02-22
AU2003288084A1 (en) 2004-06-15
CN1738833A (zh) 2006-02-22
AR041964A1 (es) 2005-06-01
NO20052149L (no) 2005-07-11
RU2323744C2 (ru) 2008-05-10
ZA200503803B (en) 2006-08-30
US20090232847A1 (en) 2009-09-17
NO20052136D0 (no) 2005-05-02
US20090104231A1 (en) 2009-04-23
NZ539998A (en) 2008-04-30
TW200502246A (en) 2005-01-16
KR20050085010A (ko) 2005-08-29
US20060246090A1 (en) 2006-11-02
GB0226722D0 (en) 2002-12-24
MA27700A1 (fr) 2006-01-02
MXPA05005203A (es) 2006-01-27
WO2004046176A1 (en) 2004-06-03
EP1560845A1 (en) 2005-08-10
WO2004046175A1 (en) 2004-06-03
MA27699A1 (fr) 2006-01-02
NO20052136L (no) 2005-07-11
CA2504654A1 (en) 2004-06-03
PL376882A1 (pl) 2006-01-09
EP1560844A1 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
US20090104231A1 (en) Vaccine
KR100874552B1 (ko) 코돈-최적화 파필로마 바이러스 서열
CA2257137A1 (en) Synthetic hepatitis c genes
KR20020068040A (ko) 키메라 면역원성 조성물 및 그들을 암호화하는 핵산
JP2011521985A (ja) Ｈｃｖ感染の予防および治療のためのワクチン
WO2014093602A1 (en) Compositions and methods for treating and preventing hepatitis c virus infection
US7074410B2 (en) Modified HCV peptide vaccines
US20090197319A1 (en) Virus-Like Particle Containing A Dengue Recombinant Replicon
CN101921310A (zh) 登革病毒特异性hla-a2限制性表位肽及应用
KR20010086226A (ko) Ｃ형 간염 바이러스의 비구조 단백질을 이용한 유전자면역법
EP1448223B1 (en) Thymosin augmentation of genetic immunization
AU2002360315B2 (en) Thymosin augmentation of genetic immunization
AU741876B2 (en) Hepatitis virus vaccines
AU2002360315A1 (en) Thymosin augmentation of genetic immunization
CN101255434A (zh) 疫苗
AU2298602A (en) Hepatitis virus vaccines

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050516

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20081112

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101025

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110824

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20101025

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I